A fragile and complex global supply chain leaves heparin vulnerable to disruption, prompting urgent calls for diversification, regulatory clarity, and investment in synthetic alternatives.
The Bethesda Declaration, a new RSV antibody for kids, amylin’s promising weight loss results, and more were industry’s need-to-know stories this week.
From a bladder transplant to a blood test for Alzheimer's disease, there were a lot of firsts this week. Check them out here along with more industry news.
From an executive order to lower drug prices to GLP-1 drug comparisons and a link between Parkinson’s disease and golf courses, it was a busy industry news week.
An executive order on drug manufacturing, a controversial HHS appointee, a diabetes drug for prostate cancers, and more were this week’s top industry headlines.
Landmark women’s health study loses funding, a promising antibody-drug conjugate for breast cancer, a schizophrenia drug setback, and more news from this week.
Promising new data shows that Factor H (CPV-104) significantly reduces inflammation and retinal degeneration in an animal model of dry age-related macular degeneration